APO-FLUTICASONE HFA 250 MCG — DIN 02510987
FLUTICASONE PROPIONATE : 250 MCG · APOTEX INC · METERED-DOSE AEROSOL · wholesale supply in Canada
Health Canada status: MARKETED
What is APO-FLUTICASONE HFA?
APO-FLUTICASONE HFA 250 MCG contains FLUTICASONE PROPIONATE : 250 MCG. It is listed in the Health Canada Drug Product Database under DIN 02510987, held by APOTEX INC, supplied as METERED-DOSE AEROSOL for INHALATION ; ORAL administration. Health Canada currently lists it as marketed, status dated 26-Apr-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-FLUTICASONE HFA used for?
APO-FLUTICASONE HFA (fluticasone propionate) is indicated for the prophylactic management of steroid-responsive bronchial asthma in adults and children (12 months of age or older). For children, this includes patients not controlled on currently available prophylactic medication.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fluticasone cost around the world?
Fluticasone is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 26 | 26 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 20 | 20 | EUR███.██ |
| Morocco | PPV (public price) | 7 | 20 | MAD███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
67 pack listings across 54 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Fluticasone pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Fluticasone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Fluticasone, across 27 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GLAXOSMITHKLINE INC | 11 | 6 | FLOVENT DISKUS, FLOVENT HFA, FLOVENT INHALERS - AEM INH-ORL 125MCG/AEM, FLOVENT INHALERS - AEM INH-ORL 250MCG/AEM, FLOVENT INHALERS - AEM INH-ORL 25MCG/AEM, +1 more | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 3 | PMS-FLUTICASONE, PMS-FLUTICASONE HFA | Sourceable in Canada |
| APOTEX INC | 3 | 3 | APO-FLUTICASONE HFA | Sourceable in Canada |
| GLAXO CANADA INC | 4 | 0 | FLOVENT INHALERS-AEM INH-ORL 25MCG/ACTUATION, FLOVENT INHALERS-AEM INH-ORL 50MCG/ACTUATION, FLOVENT INHALERS-AEM INH-ORL125MCG/ACTUATION, FLOVENT INHALERS-AEM INH-ORL250MCG/ACTUATION | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | AERMONY RESPICLICK | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 250 MCG |
|---|---|
| Dosage form | METERED-DOSE AEROSOL |
| Route | INHALATION ; ORAL |
| Pack configuration (monograph) | 120 dose containers |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fluticasone |
|---|---|
| ATC code | R03BA05 |
| AHFS class | 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02510987 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2510987 |
| Brand name | APO-FLUTICASONE HFA |
| Generic / active ingredient | FLUTICASONE PROPIONATE : 250 MCG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | R03BA05 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03BA |
| Current status | MARKETED |
| Status date | 26-Apr-2021 |
| Original market date | 2022-10-03 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 27 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FLUTICASONE HFA | 125 MCG | METERED-DOSE AEROSOL | APOTEX INC | MARKETED | 02526557 |
| APO-FLUTICASONE HFA | 50 MCG | AEROSOL, METERED DOSE | APOTEX INC | MARKETED | 02528428 |
| FLOVENT DISKUS | 100 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | 02237245 |
| FLOVENT DISKUS | 250 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | 02237246 |
| FLOVENT DISKUS | 500 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | 02237247 |
| FLOVENT HFA | 125 MCG | METERED-DOSE AEROSOL | GLAXOSMITHKLINE INC | MARKETED | 02244292 |
| FLOVENT HFA | 50 MCG | METERED-DOSE AEROSOL | GLAXOSMITHKLINE INC | MARKETED | 02244291 |
| FLOVENT HFA | 250 MCG | METERED-DOSE AEROSOL | GLAXOSMITHKLINE INC | MARKETED | 02244293 |
| PMS-FLUTICASONE HFA | 250 MCG | METERED-DOSE AEROSOL | PHARMASCIENCE INC | MARKETED | 02503131 |
| PMS-FLUTICASONE HFA | 50 MCG | METERED-DOSE AEROSOL | PHARMASCIENCE INC | MARKETED | 02503115 |
2 · Same class — other molecules in ATC R03BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fluticasone | AERMONY RESPICLICK · APO-FLUTICASONE HFA · FLOVENT DISKUS · FLOVENT HFA · +10 more | 27 | 12 | Yes |
| Budesonide | PULMICORT NEBUAMP 0.125 MG/ML · PULMICORT NEBUAMP 0.25 MG/ML · PULMICORT NEBUAMP 0.5 MG/ML · PULMICORT TURBUHALER · +2 more | 12 | 12 | Yes |
| Mometasone | ASMANEX TWISTHALER | 3 | 3 | Yes |
| Beclometasone | ALTI-BECLOMETHASONE DIPROPIONATE INHALER 50MCG/MD · BECLODISK - PWR INH 100MCG/BLISTER · BECLODISK - PWR INH 200MCG/BLISTER · BECLODISK PWR 100MCG/BLISTER · +12 more | 17 | 2 | Yes |
| Ciclesonide | ALVESCO | 3 | 2 | Yes |
| Fluticasone Furoate | ARNUITY ELLIPTA | 2 | 2 | Yes |
| Flunisolide | BRONALIDE INHAL 250MCG/AEM | 1 | 0 | Not in Canada |
| Triamcinolone | AZMACORT | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03BB | Aclidinium Bromide · Glycopyrronium Bromide · Ipratropium Bromide · Tiotropium Bromide · Umeclidinium Bromide | 37 | 15 |
| R03BC | Cromoglicic Acid · Nedocromil | 11 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-FLUTICASONE HFA called?
The same molecule, Fluticasone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FLIXOTIDE DISKUS | Latin | Morocco |
| CUTIVATE | Latin | Morocco |
| FLIXOTIDE | Latin | Morocco |
| FLOTEC | Latin | Morocco |
| FLIXONASE | Latin | Morocco |
| FLUZAIR | Latin | Morocco |
| NAZAIR | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.